COVID 19, SARS-CoV 2, Viral Infection
Conditions
Keywords
COVID 19, SARS-CoV 2, Viral infection, Multivirus T cell
Brief summary
This is a dose-finding safety trial followed by a randomized pilot trial comparing administration of SARS-CoV2-specific T cells (SARS-CoVSTs) to standard of care treatment in hospitalized patients with COVID19 who are at high risk of requiring mechanical ventilation. The SARS-CoVSTs lines have been made at Baylor College of Medicine from healthy donors who have made a full recovery from COVID19. These cell lines were frozen for later use and will be thawed and used to treat patients who meet the eligibility criteria.
Detailed description
The first part of this study is to identify the maximum tolerated dose (MTD) of allogeneic SARS-CoV2-specific T cells (SARS-CoVSTs) for patients with COVID19 with high risk of progression to mechanical ventilation. The 3 dose levels (DL) are: DL1: 1x10\^7 cells (flat dose) DL2: 2x10\^7 cells (flat dose) DL3: 4x10\^7 cells (flat dose) Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level. After the dose finding phase is complete and the MTD established, a randomized trial will be conducted. Patient will be randomized 1:1 using the permuted block method with a block size of 4 (2 in the treatment arm and 2 in the control arm) to receive treatment with SARS-CoVSTs or routine treatment per institutional standards. All enrolled patients will undergo the following evaluations: * Physical exam and history including height and weight * SARS-CoV-2 test * Blood tests * Chest X-ray or chest CT Scan if not already done in the past 48 hours. * A urine pregnancy test, when applicable Patients randomized to receive SARS-CoVSTs will be pre-medicated with Benadryl and Tylenol. The cells will be thawed and given through an intravenous line. Patients will be monitored for infusion side effects for up to 14 days or until infusion side effects have completely resolved, whichever is longer. Blood will be drawn before the infusion and then up to daily for 14 days or until the patient is discharged from the hospital. Optional blood samples will be drawn at 2, 3 and 6 months after infusion. Study participation will last 6 months after the date of infusion.
Interventions
BIOLOGICALDose Finding Phase (MTD)
Enrollment to the dose escalation phase will be staggered. The first patient enrolled on each of the 3 dose levels (DL1, DL2 and DL3) will have to complete the 14-day toxicity monitoring window prior to enrollment of the next patients. Prior to dose escalation, all patients at a particular dose level should have completed the minimum 14-day toxicity monitoring window before enrolling to a higher dose level.
BIOLOGICALPartially HLA-matched SARS-CoVSTs
Infusion of SARS-CoVSTs at the MTD level as determined in the Dose Finding Phase
OTHERRoutine care (no SARS-CoVSTs)
Patients receive routine care for COVID19 per institutional standards (including antivirals such as remdesivir or other FDA-EUA approved products and thromboprophylaxis).
Sponsors
Center for Cell and Gene Therapy, Baylor College of Medicine
AlloVir
The Methodist Hospital Research Institute
Baylor College of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. SARS-CoV-2 infection confirmed by polymerase chain reaction assay (PCR) from a nasopharyngeal swab or other accepted specimen type. (If testing was performed ≥ 5 days before enrollment, this must be repeated and accept only if positive again). Date of COVID test must be ≤ 5 days prior to infusion. 2. Currently hospitalized adult patient (≥ 18 years of age) requiring medical care for COVID19 3. Peripheral oxygen saturation (SpO2) ≥ 92% on room air 4. Hgb ≥ 7.0 gm/dl 5. Negative pregnancy test (if applicable) 6. Patient or parent/guardian capable of providing informed consent (may be obtained electronically) 7. Evidence of pulmonary infiltrates on chest imaging. Any chest imaging findings which would be consistent with COVID19 would qualify (Eg: ground glass opacities, multifocal infiltrates etc.) 8. High risk of requiring mechanical ventilation as defined by at least two of the following: 1. Age ≥ 60 years of age 2. Age ≥ 75 years of age (counts as meeting two criteria) 3. Hypertension (HTN) 4. Chronic cardiovascular disease other than HTN (eg: Coronary artery disease, congestive heart failure or cardiomyopathies). 5. Diabetes Mellitus 6. Obesity (BMI ≥ 30) 7. Obesity (BMI ≥ 40, counts as meeting two criteria) 8. Active cancer diagnosis or ongoing (within 3 months) cytotoxic chemo/ radio-therapy for a cancer 9. Post-hematopoeitic stem cell or solid organ transplantation status 10. Immunodeficiency states including HIV infection on antiretroviral therapy (except those listed as
Exclusion criteria
#1, #7 and #10) as determined by the treating physician (eg: receiving immunosuppressive therapy like rituximab or congenital immunodeficiency syndromes, prior treatment with chemotherapy greater than 3 months ago but per investigators discretion could have lingering effects on the immune system, eg: chemotherapy regimens for lymphomas, ALL or AML etc.) 11. Chronic obstructive pulmonary disease (COPD) 12. Current everyday smoker 13. Chronic kidney disease (eGFR \< 30 mL/min/1.73 m2 ) 14. Bronchial asthma (on active treatment prior to admission, eg. Use of rescue inhalers or inhaled corticosteroids or other treatments to prevent/treat attacks).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Escalation Phase: Rate of Dose Limiting Toxicities by CTCAE 5.0 [14 days post infusion] | 14 days post infusion | Defined as the proportion of subjects with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment. A dose limiting toxicity is defined as any acute GvHD (\> grade 2), grade ≥3 CRS or ICANS, grade ≥3 hematologic toxicity or grade ≥3 non-hematologic adverse events related to the T cell product within 14 days of the VST infusion and that are not due to pre-existing conditions as defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5. |
| Randomized Trial: Rate of Clinical Response as assessed by the World Health Organization (WHO) Ordinal Scale [7 days post-randomization or hospital discharge] | 7 Days post-randomization or at time of hospital discharge | Clinical Response rate is defined as the proportion of subjects reporting an increase in 2 or more points on the WHO Ordinal Scale. \[Scored on a scale from 0 to 8; where 0 = Uninfected and 8 =Dead\] or until patient is discharged. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Randomized Trial: Rate of Treatment-related adverse events (tAE) by CTCAE 5.0 [14 days post-randomization] | 14 days post-randomization | Defined as the proportion of subjects with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment. Treatment-related adverse events (tAE) are defined as any acute GvHD (\> grade 2), grade ≥3 CRS or ICANS, grade ≥3 hematologic toxicity or grade ≥3 non-hematologic adverse events related to the T cell product within 14 days of the VST infusion and that are not due to pre-existing conditions as defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5. |
Countries
United States
Outcome results
None listed